These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16305517)

  • 1. Heterogeneity of synthetic factor Xa inhibitors.
    Gerotziafas GT; Samama MM
    Curr Pharm Des; 2005; 11(30):3855-76. PubMed ID: 16305517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor Xa inhibitors: new anti-thrombotic agents and their characteristics.
    Ieko M; Tarumi T; Nakabayashi T; Yoshida M; Naito S; Koike T
    Front Biosci; 2006 Jan; 11():232-48. PubMed ID: 16146728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemistry and clinical pharmacology of new anticoagulant agents.
    Samama MM; Gerotziafas GT; Elalamy I; Horellou MH; Conard J
    Pathophysiol Haemost Thromb; 2002; 32(5-6):218-24. PubMed ID: 13679646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).
    Samama MM; Gerotziafas GT
    Thromb Res; 2003 Jan; 109(1):1-11. PubMed ID: 12679126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short- and long-acting synthetic pentasaccharides.
    Koopman MM; Büller HR
    J Intern Med; 2003 Oct; 254(4):335-42. PubMed ID: 12974872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies.
    Leone G; Rossi E; Leone AM; De Stefano V
    Curr Med Chem Cardiovasc Hematol Agents; 2004 Oct; 2(4):311-26. PubMed ID: 15320782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacology of direct and indirect factor Xa inhibitors.
    Rupprecht HJ; Blank R
    Drugs; 2010 Nov; 70(16):2153-70. PubMed ID: 20964458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors.
    Bauer KA; Hawkins DW; Peters PC; Petitou M; Herbert JM; van Boeckel CA; Meuleman DG
    Cardiovasc Drug Rev; 2002; 20(1):37-52. PubMed ID: 12070533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Factor Xa : a potential target for the development of new anticoagulants.
    Alexander JH; Singh KP
    Am J Cardiovasc Drugs; 2005; 5(5):279-90. PubMed ID: 16156684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in clinical trials of the direct and indirect selective Factor Xa inhibitors.
    Porcari AR; Chi L; Leadley R
    Expert Opin Investig Drugs; 2000 Jul; 9(7):1595-600. PubMed ID: 11060763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New anticoagulants.
    Weitz JI; Bates SM
    J Thromb Haemost; 2005 Aug; 3(8):1843-53. PubMed ID: 16102051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
    Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
    Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
    Graff J; Picard-Willems B; Harder S
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery.
    Agnelli G; Sonaglia F; Becattini C
    Curr Pharm Des; 2005; 11(30):3885-91. PubMed ID: 16305519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment and prevention of venous thromboembolic events: present and future antithrombotic agents].
    Drouet L
    Bull Acad Natl Med; 2003; 187(1):85-96; discussion 96-7. PubMed ID: 14556456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developments in factor Xa inhibitors for the treatment of thromboembolic disorders.
    Lee YK; Player MR
    Med Res Rev; 2011 Mar; 31(2):202-83. PubMed ID: 19967784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological strategies for inhibition of thrombin activity.
    Alban S
    Curr Pharm Des; 2008; 14(12):1152-75. PubMed ID: 18473863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
    Bhunia SS; Roy KK; Saxena AK
    J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins.
    Rezaie AR
    Thromb Haemost; 2003 Jan; 89(1):112-21. PubMed ID: 12540961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats.
    Sato K; Taniuchi Y; Kawasaki T; Hirayama F; Koshio H; Matsumoto Y
    Eur J Pharmacol; 1998 Apr; 347(2-3):231-6. PubMed ID: 9653887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.